US and European regulators may like the idea of creating a global reference standard for biosimilars, but believe legal and other issues associated with it likely mean the idea is years away from being implemented.
A global reference standard would set one approved version of an innovator product as the basis for a biosimilar's development
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?